nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.04.2015 | Original article

Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer

An interim analysis of 312 cases

verfasst von: Harun Badakhshi, M.D., PhD, Reinhold Graf, M.D., Volker Budach, M.D., Ph.D., Peter Wust, M.D., Ph.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The biochemical relapse-free survival (bRFS) rate after treatment with permanent iodine-125 seed implantation (PSI) or combined seeds and external beam radiotherapy (COMB) for clinical stage T1–T2 localized prostate cancer is a clinically relevant endpoint. The goal of this work was to evaluate the influence of relevant patient- and treatment-related factors.

Materials and methods

The study population comprised 312 consecutive patients treated with permanent seed implantation. All patients were evaluable for analysis of overall survival (OS) and disease-specific survival (DSS), 230 for bRFS, of which 192 were in the PSI group and 38 in the COMB group. The prescribed minimum peripheral dose was 145 Gy for PSI, for COMB 110 Gy implant and external beam radiotherapy of 45 Gy. The median follow-up time was 33 months (range 8–66 months). bRFS was defined as a serum prostate-specific antigen (PSA) level ≤ 0.2 ng/ml at last follow-up.

Results

Overall, the actuarial bRFS at 50 months was 88.4 %. The 50-month bRFS rate for PSI and COMB was 90.9 %, and 77.2 %, respectively. In the univariate analysis, age in the categories ≤ 63 and > 63 years (p < 0.00), PSA nadir (≤ 0.5 ng/ml and > 0.5 ng\ml) and PSA bounce (yes/no) were the significant predicting factors for bRFS. None of the other patient and treatment variables (treatment modality, stage, PSA, Gleason score, risk group, number of risk factors, D90 and various other dose parameters) were found to be a statistically significant predictor of 50-month bRFS.

Conclusion

The biochemical failure rates were low in this study. As a proof of principle, our large monocenteric analysis shows that low-dose-rate brachytherapy is an effective and safe procedure for patients with early stage prostate cancer.

Wust P, Postrach J, Kahmann F, Henkel T, Graf R, Cho CH, Budach V, Böhmer D (2008) Postimplantation analysis enables improvement of dose–volume histograms and reduction of toxicity for permanent seed implantation. Int J Radiat Oncol Biol Phys 71:28–35CrossRefPubMed

Peinemann F, Grouven U, Bartel C, Sauerland S, Borchers H, Pinkawa M, Heidenreich A, Lange S (2011) Permanent interstitial low-dose rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 60:881–893CrossRefPubMed

Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA (2004) Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy >or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 8:25–33CrossRef

Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, Jewett M, Fleshner N (2011) Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 29:362–368CrossRefPubMed

Sylvester JE, Grimm PD, Wong J et al (2011) Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I-125 prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 81:376–381CrossRefPubMed

Machtens S, Baumann R, Hagemann J, Warszawski A, Meyer A, Karstens JH, Jonas U (2006) Long-term results of interstitial brachytherapy (LDR-brachytherapy) in the treatment of patients with prostate cancer. World J Urol 24:289–295CrossRefPubMed

Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the prostate cancer results study group. BJU Int 109:22–29CrossRefPubMed

Guckenberger M, Lawrenz I, Flentje M (2014) Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT. Strahlenther Onkol 190:48–53CrossRefPubMed

Lohm G, Lütcke J, Jamil B, Höcht S, Neumann K, Hinkelbein W, Wiegel T, Bottke D (2014) Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy: long-term follow-up of a single-center survey. Strahlenther Onkol 190:727–731CrossRefPubMed

10.

Yoshida K, Yamazaki H, Takenaka T, Kotsuma T, Yoshida M, Masui K, Yoshioka Y, Narumi Y, Oka T, Tanaka E (2014) High-dose-rate interstitial brachytherapy in combination with androgen deprivation therapy for prostate cancer: are high-risk patients good candidates? Strahlenther Onkol 2014 May 17

11.

Merrick GS, Zelefsky M, Sylvester K (2013) American Brachytherapy Society Prostate Low-Dose Rate Task Group. http://www.americanbrachytherapy.org/guidelines/prostate_low-doseratetaskgroup.pdf. Accessed: 13 October 2014

12.

Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ (2012) American Brachytherapy Society. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11:6–19CrossRefPubMed

13.

Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, Goldsmith BJ, Horwitz EM, Ibbott GS, Lee WR, Nag S, Suh WW, Potters L (2011) American Society for Radiation Oncology; American College of Radiology. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 79:335–341CrossRefPubMed

14.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2011) European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71CrossRefPubMed

15.

Wust P, von Borczyskowski DW, Henkel T, Rosner C, Graf R, Tilly W, Budach V, Felix R, Kahmann F (2004) Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy. Radiother Oncol 73:39–48CrossRefPubMed

16.

Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E (2009) Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol 27:607–612CrossRefPubMed

17.

Battermann JJ, Boon TA, Moerland MA (2004) Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 71:23–28CrossRefPubMed

18.

Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE (2000) Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47:1261–1266CrossRefPubMed

19.

Blasko JC, Grimm PD, Sylsvester JE, Cavanagh W (2000) The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 57:273–278CrossRefPubMed

20.

Dattoli M, Wallner K, True L, Cash J, Sorace R (2003) Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patientswith higher risk prostate carcinoma: influence of prostatic acid phosphatase. Cancer 97:979–983CrossRefPubMed

21.

Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG (2009) Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 75:16–22CrossRefPubMed

22.

Aaltomaa SH, Kataja VV, Lahtinen T, Palmgren JE, Forsell T (2009) Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy- morbidity and outcome results. Radiother Oncol 91:213–216CrossRefPubMed

23.

Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA (2002) Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20:3376–3385CrossRefPubMed

24.

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597CrossRefPubMed

25.

Iselin CE, Robertson JE, Paulson DF (1999) Radical perineal prostatectomy: oncological outcome during a 20-year period. J Urol 161:163–168CrossRefPubMed

26.

Le Fur E, Malhaire JP, Baverez D, Delage F, Perrouin-Verbe MA, Schlurmann F, Guerif S, Fournier G, Pradier O, Valeri A (2012) Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer. Strahlenther Onkol 188:1091–1095CrossRefPubMed

27.

Goldner G, Pötter R, Battermann JJ, Schmid MP, Kirisits C, Sljivic S, van Vulpen M (2012) Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients. Strahlenther Onkol 188:305–310CrossRefPubMed

Titel: Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer
An interim analysis of 312 cases
verfasst von: Harun Badakhshi, M.D., PhD
Reinhold Graf, M.D.
Volker Budach, M.D., Ph.D.
Peter Wust, M.D., Ph.D.
Publikationsdatum: 01.04.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 4/2015
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0762-6

Springer Medizin

Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer

An interim analysis of 312 cases